Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Ovarian Neoplasms 19Small Cell Lung Carcinoma 9Carcinoma, Ovarian Epithelial 8Fallopian Tube Neoplasms 7Recurrence 6Brain Neoplasms 5Neuroblastoma 4Neoplasms 4Lung Neoplasms 4Medulloblastoma 3Glioma 3Central Nervous System Neoplasms 3Uterine Cervical Neoplasms 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Meningeal Carcinomatosis 2Familial ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Optic Nerve Glioma 1Oligodendroglioma 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Topotecan × Clear all
NCT00437073 2015-10-15

Brain Metastases In ErbB2-Positive Breast Cancer

GlaxoSmithKline

Phase 2 Terminated
22 enrolled 8 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00006032 2012-12-11

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡